Bank of America Issues Pessimistic Forecast for WAVE Life Sciences (NASDAQ:WVE) Stock Price

WAVE Life Sciences (NASDAQ:WVE) had its price target dropped by research analysts at Bank of America from $38.00 to $21.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Bank of America‘s price target would suggest a potential upside of 230.19% from the stock’s current price.

Other analysts also recently issued research reports about the stock. Wedbush lifted their target price on shares of WAVE Life Sciences from $33.00 to $35.00 and gave the company an “outperform” rating in a report on Friday, March 6th. Morgan Stanley set a $28.00 price target on WAVE Life Sciences in a research report on Monday, December 8th. Raymond James Financial reaffirmed an “outperform” rating and issued a $21.00 price objective on shares of WAVE Life Sciences in a research note on Monday, December 8th. Wall Street Zen downgraded WAVE Life Sciences from a “hold” rating to a “sell” rating in a report on Saturday, February 7th. Finally, HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of WAVE Life Sciences in a research note on Monday, March 2nd. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $31.38.

WAVE Life Sciences Price Performance

Shares of WVE stock opened at $6.36 on Friday. The firm has a market cap of $1.20 billion, a PE ratio of -5.21 and a beta of -1.77. The company has a 50-day moving average of $12.93 and a two-hundred day moving average of $11.22. WAVE Life Sciences has a 1-year low of $5.02 and a 1-year high of $21.73.

WAVE Life Sciences (NASDAQ:WVE) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.02). WAVE Life Sciences had a negative net margin of 478.35% and a negative return on equity of 85.69%. The company had revenue of $17.25 million for the quarter, compared to analyst estimates of $15.68 million. Sell-side analysts anticipate that WAVE Life Sciences will post -1.14 EPS for the current fiscal year.

Insider Buying and Selling at WAVE Life Sciences

In other WAVE Life Sciences news, CEO Paul Bolno sold 10,480 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $13.45, for a total value of $140,956.00. Following the completion of the transaction, the chief executive officer owned 275,520 shares of the company’s stock, valued at $3,705,744. This trade represents a 3.66% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Chandra Vargeese sold 3,228 shares of the company’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $13.45, for a total value of $43,416.60. Following the sale, the insider directly owned 408,246 shares in the company, valued at $5,490,908.70. This represents a 0.78% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 61,748 shares of company stock worth $907,809. 23.98% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On WAVE Life Sciences

Several large investors have recently bought and sold shares of the stock. CWM LLC raised its position in WAVE Life Sciences by 6,729.0% in the 4th quarter. CWM LLC now owns 2,117 shares of the company’s stock valued at $36,000 after purchasing an additional 2,086 shares in the last quarter. Smartleaf Asset Management LLC grew its position in shares of WAVE Life Sciences by 645.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 2,243 shares of the company’s stock worth $38,000 after buying an additional 1,942 shares in the last quarter. Bessemer Group Inc. increased its stake in shares of WAVE Life Sciences by 1,156.3% during the third quarter. Bessemer Group Inc. now owns 9,925 shares of the company’s stock worth $72,000 after buying an additional 9,135 shares during the period. Russell Investments Group Ltd. increased its stake in shares of WAVE Life Sciences by 1,441.6% during the third quarter. Russell Investments Group Ltd. now owns 9,928 shares of the company’s stock worth $73,000 after buying an additional 9,284 shares during the period. Finally, Ameritas Investment Partners Inc. raised its holdings in WAVE Life Sciences by 18.7% in the second quarter. Ameritas Investment Partners Inc. now owns 11,444 shares of the company’s stock valued at $74,000 after acquiring an additional 1,802 shares in the last quarter. Hedge funds and other institutional investors own 89.73% of the company’s stock.

More WAVE Life Sciences News

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: Company press release: management highlighted six‑month, placebo‑adjusted improvements in body composition (240 mg single dose produced ~14% visceral fat reduction, ~5% total fat reduction, +2% lean mass, ~3.3% waist circumference reduction) and continued safety/tolerability — data that supports the therapy’s mechanism and future development plans. Wave press release
• Positive Sentiment: Management commentary / transcripts emphasize the visceral‑fat and body‑composition signal and durability at six months, which supporters point to as a differentiated outcome versus pure body‑weight endpoints. Seeking Alpha transcript
• Positive Sentiment: Analyst positioning remains mixed but includes continued conviction from some firms: Bank of America kept a Buy rating (PT cut), Wells Fargo kept Overweight (PT cut), Truist upgraded to Strong‑Buy and Mizuho issued bullish commentary — these voices can limit downside and attract buyers after the sell‑off. Benzinga (analyst notes)
• Neutral Sentiment: Independent outlets and investor notes characterize the data as “clinically interesting” on body composition but still early‑stage and not yet persuasive on meaningful weight loss — meaning future development and larger trials will determine value. ProactiveInvestors report
• Negative Sentiment: Market reaction: shares plunged >50% after investors focused on the modest ~0.9% body‑weight reduction at six months and the higher‑dose readout that “failed to show a clear improvement” by some measures — the gap between body‑composition signals and headline weight loss disappointed traders. Reuters
• Negative Sentiment: Investor/legal risk: a law firm is publicizing an investigation into potential claims by shareholders, adding litigation overhang and downward pressure on sentiment. GlobeNewswire (Johnson Fistel)
• Negative Sentiment: Analyst downgrades and target cuts followed the update; multiple outlets report steep target cuts and downgrades that reflect lower near‑term expectations and have likely amplified selling pressure. Seeking Alpha downgrade

About WAVE Life Sciences

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.